Results 91 to 100 of about 132,304 (290)

Protection and diagnostic interference induced by heat-inactivated, phage-inactivated and live vaccine prototypes against animal tuberculosis

open access: yesFrontiers in Veterinary Science
IntroductionVaccination emerges as a promising cost-effective tool to reduce the impact and spread of animal tuberculosis, especially in regions where test-and-slaughter eradication strategy is socioeconomically unfeasible or unfruitful for different ...
Leire Fernández-Veiga   +14 more
doaj   +1 more source

The Update, February 13, 2012 [PDF]

open access: yes, 2012
The Update is a bi-weekly web newsletter published by the Iowa Department of Public Health's Bureau of Family Health. It is posted the second and fourth week of every month, and provides useful job resource information for departmental health care ...

core  

In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae [PDF]

open access: yes, 2018
Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a Gram-negative bacterium that represents the main cause of porcine pleuropneumonia in pigs, causing significant economic losses to the livestock industry worldwide. A.
A Hensel   +55 more
core   +6 more sources

Substituent‐Based Modulation of Self‐Assembly and Immunogenicity of Amphipathic Peptides

open access: yesAdvanced Science, EarlyView.
This study systematically investigates how positional and subtle changes, such as substituents on the phenyl ring attached to short amphipathic peptides, influence their self‐assembly, fibril morphology, and immunogenic responses. ABSTRACT Self‐assembled peptide‐based biomaterials provide versatile platforms for biomedical uses, featuring customizable ...
Anirban Das   +13 more
wiley   +1 more source

Long-lasting cross-protection against influenza A by neuraminidase and M2e-based immunization strategies [PDF]

open access: yes, 2016
There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells provide protection against pandemic influenza viruses. Here, we compared protection and CD8+ T cell responses following challenge with H1N1 2009 pandemic and
Callewaert, Nico   +9 more
core   +2 more sources

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang   +7 more
wiley   +1 more source

SARS CoV subunit vaccine: Antibodymediated neutralisation and enhancement [PDF]

open access: yes, 2012
1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2.
Altmeyer, R   +14 more
core   +1 more source

Inactivated Viral Vaccines

open access: yes, 2014
Inactivated vaccines have been used for over a century to induce protection against viral pathogens. This established approach of vaccine production is relatively straightforward to achieve and there is an augmented safety profile as compared to their live counterparts.
Sanders, Barbara   +2 more
openaire   +1 more source

ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion

open access: yesAdvanced Science, EarlyView.
ZBTB21 is a transcription factor that epigenetically suppresses pyroptosis and MHC‐I antigen presentation, enabling tumor immune evasion. Genetic ablation of ZBTB21 activates pyroptotic cell death and enhances antigen presentation, recruiting CD8+ T cells to overcome immune checkpoint blockade resistance.
Lei Zhao   +12 more
wiley   +1 more source

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

open access: yes, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy